Human papilloma virus and HIV/AIDS;Virus del papiloma humano y virus de la inmunodeficiencia humana/sida

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue SUPPL.2, 2006, Pages 40-46

  Sirera, Guillem ^a,b   Videla, Sebastià ^b   Herranz, Pedro ^c   Corzo Delgado, Juan E ^d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Fundació Lluita Contra la SIDA ^*  (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Carcinoma; Cervix; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS; CONDYLOMA; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MOUTH CAVITY; NONHUMAN; OPPORTUNISTIC INFECTION; PENIS; PREVALENCE; REVIEW; TUMOR BIOPSY; UTERINE CERVIX; UTERINE CERVIX CANCER; WART VIRUS;

EID: 34548561921     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13096049     Document Type: Review

References (52)

1. Zur Hausen H. Human genital cancer: synergism between two virus infections and or synergism between a virus infection and initiating events? Lancet. 1982;2:1370-2.
2. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J N Cancer Inst. 1993;85:958-64.
3. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802.
4. Muñoz N, Bosch X, De San Jose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
5. Koutsky LA, Ault KA, Weeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-51.
6. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6,11,16,18) L1 virus like particle in young women: a randomised double blind placebo controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-8.
7. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65.
8. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
9. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500-10.
10. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001; 164:1017-25.
11. Wright TC, Ellerbrock TV, Busch TJ, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. Obstet Gynecol. 1994;84:591-7.
12. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA. 2005;293:1471-6.
13. Duerr A, Paramsothy P, Jamieson D, Heilig CM, Klein RS, Cu-Uvin S, et al. Effect of HIV infection on atypical squamous cells of undetermined significance. CID. 2006;42:855-61.
14. Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV study group. JAIDS. 1999;21:33-41.
15. Woodhouse SL, Stastny JF, Styer PE, Kennedy M, Praestgaard AH, Davey DD. Interobserver variability in subclassification of squamous intraepithelial lesions. Results of the college of American Pathologits interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med. 1999; 123:1079-84.
16. Fahet MT, Irwing L, Masaskill O. Meta analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-9.
17. Nanda K, McCroy DC, Myers E, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Int Med. 2000;132:810-9.
18. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989;262:931-4.
19. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of the minimally abnormal Papanicolaou test. Obstet Gynecol. 1998;91:973-6.
20. Sirera G, Videla S, Castellá E, Cavalle L, Grane N, Llatjos M, et al. Contribución de la captura de híbridos de segunda generación del virus del papillota humano en el cribado de afección cervical en mujeres con infección por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2005;125:127-31.
21. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminate and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002; 359:108-13.
22. Gilles C, Manigart Y, Konopnicki D, Barlow P, Rozenberg S. Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status. Gynecol Oncol. 2005;96:112-8.
23. Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV positive women. JAIDS. 2005;39:412-8.
24. Stephen Goldstone S. Anal dysplasia in men who have sex with men. The AIDS Reader. 1999;9:204-8.
25. Kreuter A, Brockmeyer NH, Hochdorfer B, Weissenberg SJ, Stücker M, Swoboda J, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol. 2005;55: 603-8.
26. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts R, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous, intraepithelial lesions in HIV positive and HIV negative homosexual and bisexual men. JAIDS. 1998;17:314-9.
27. Holly E, Ralston M, Darragh T, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Nat Cancer Inst. 2001;93:843-9.
28. Sirera G, Ballesteros A, Piñol M, Cañadas M, Lletjós M, Videla S, et al. High prevalence of human papillomavirus infection in male positive for human immunodeficiency virus, even without anal intraepithelial lesions. 13th Conference on retroviruses and opportunistic infections. February 5-8, 2006, Colorado, Denver (poster no. 806).
29. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138:453-9.
30. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum. 2001;44:506-12.
31. Sirera G, Videla S, Piñol M, Cañadas MP, Llatjos M, Ballesteros AL, et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV positive men. AIDS. 2006;20:1201-4.
32. Ching-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127-34.
33. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol. 2001;137:14-6.
34. Herat A, Shirato K, Damian DL, Finlayson R, Whitfeld M. Invasive squamous cell carcinoma arising in refractory perianal Bowen's disease in a HIV-positive individual. Australas J Dermatol. 2006;47:120.
35. Aboulafia DM, Gibbons S. Penile cancer and human papillomavirus (HPV) in a human immunodeficiency virus HIV infected patient. Cancer Invest. 2001;19:266-72.
36. Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, et al. Presence of high risk human papillomavirus DNA in penile carcinoma predicts favourable outcome in survival. Int J Cancer. 2006;119:1078-81.
37. MacLean R. Odds of penile HPV are reduced for circumcised men and condoms users. Int Fam Plan Perspect. 2005;31:42.
38. Schwartz SR, Yueh B, Mc Dougall JK, Daling JR, Schwartz SM. Human Papillomavirus infection and survival in oral squamous cell cancer: a population based study. Otolaryngol Head Neck Surg. 2001;125:1-9.
39. Rodrigues LKE, Baker T, Maurer T. Cutaneous warts in HIV-positive patients undergoing highly active antiretroviral therapy. Arch Dermatol. 2001; 137:1103-4.
40. Greenspan D, Canchola A, MacPhail L, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet. 2001; 357:1411-2.
41. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV seropositive women receiving highly active antiretroviral therapy. AIDS. 1998;12:1459-64.
42. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV related diseases. Antivir Therapy. 2004;9:13-22.
43. Palefsky JM, Holly E, Efirdc J, Da Costa M, Jay N, Berry JM, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV positive men who have sex with men. AIDS. 2005;19:1407-14.
44. Haga T, Kim SH, Jensen RH, Darragh T, Palefsky JM. Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV positive and HIV negative men. JAIDS. 2001;26:256-62.
45. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull WHO. 2004;82:454-61.
46. De Sanjosé S, Almirall RR, Lloveras B, Font R, Diaz M, Muñoz N, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis. 2003;30:788-93.
47. Wilson J. Treatment of genital warts-what's the evidence. Int J STD AIDS. 2002;13:216-20.
48. Baldwin S, Wallace D, Papenfuss M, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis. 2004;31:601-7.
49. Richardson H, Abrahamowicz M, Teiller PP, Kelsall G, Du Berger R, Ferenczy A, et al. Modifiable risk factors associated with clearance of type specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev. 2005;14:1149-56.
50. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta analysis. Sex Transm Dis. 2002;29:725-35.
51. Hogewoning CJ, Blleker MC, Van den Brule AJ, Voorhorst FJ, Snijders PJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer. 2003;107:811-6.
52. Epstein RJ. Primary prevention of human papillomavirus dependent neoplasia: no condom, no sex. Eur J Cancer. 2005;41:2595-600.